Patents Assigned to Cytos Biotechnology AG
-
Publication number: 20130115189Abstract: The present invention provides compositions, pharmaceutical compositions and vaccines for the treatment, amelioration and/or prophylaxis of type II diabetes. The compositions, pharmaceutical compositions and vaccines of the invention comprise a virus-like particle of an RNA bacteriophage and an antigen, wherein said antigen comprises an interleukin-1 beta (IL-1?) mutein. When administered to an animal, preferably to a human, said compositions, pharmaceutical compositions, and vaccines induce efficient immune responses, in particular antibody responses, wherein typically and preferably said antibody responses are directed against IL-1?. Thus, the invention provides methods of treating, ameliorating or preventing type II diabetes by way of active immunization against IL-1?.Type: ApplicationFiled: September 9, 2010Publication date: May 9, 2013Applicant: Cytos Biotechnology AGInventors: Martin F. Bachmann, Gunther Spohn, Patrik Maurer
-
Patent number: 8344111Abstract: The invention relates to recombinantly produced human monoclonalantibodies which are specifically binding nicotine and to nucleic acids encoding the same. The invention further relates to the use of such antibodies in the treatment of nicotine addiction.Type: GrantFiled: September 11, 2008Date of Patent: January 1, 2013Assignee: Cytos Biotechnology AGInventors: Martin Bachmann, Monika Bauer, Roger Beerli, Patrik Maurer
-
Publication number: 20120322103Abstract: This invention provides a robust fermentation process for the expression of a capsid protein of a bacteriophage which is forming a VLP by self-assembly, wherein the process is scalable to a commercial production scale and wherein the expression rate of the capsid protein is controlled to obtain improved yield of soluble capsid protein. This is achieved by combining the advantages of fed-batch culture and of lactose induced expression systems with specific process parameters providing improved repression of the promoter during the growth phase and high plasmid retention throughout the process.Type: ApplicationFiled: December 22, 2011Publication date: December 20, 2012Applicant: Cytos Biotechnology AGInventors: Marcel EMMERLING, Frank Hennecke, Holger Pfründer, Martin Rhiel, Philipp Steiner
-
Publication number: 20120263743Abstract: The present invention is in the fields of medicine, public health, immunology, molecular biology and virology. The invention provides compositions, vaccine compositions and pharmaceutical compositions for the treatment, amelioration and/or prevention of influenza. The compositions, vaccine compositions and pharmaceutical compositions of the invention comprise a virus-like particle of an RNA bacteriophage and at least one antigen, wherein said at least one antigen is an ectodomain of an influenza virus hemagglutinin protein or a fragment of said ectodomain of an influenza virus hemagglutinin protein. When administered to an animal, preferably to a human, said compositions, vaccine compositions and pharmaceutical compositions efficiently induce immune responses, in particular antibody responses, wherein typically and preferably said antibody responses are directed against influenza virus. Thus, the invention further provides methods of treating, ameliorating and/or preventing influenza virus infection.Type: ApplicationFiled: April 30, 2010Publication date: October 18, 2012Applicant: Cytos Biotechnology AGInventors: Martin Bachmann, Andrea Jegerlehner, Philippe Saudan
-
Publication number: 20120214976Abstract: The invention provides a process for the purification recombinantly expressed, self-assembled VLP from the homogenate of a bacterial host, wherein the process can be scaled up to a commercial production scale in a cost effective manner. The process comprises a first chromatography using an anion exchange matrix, a second chromatography using hydroxyapatite and, optionally, a size exclusion chromatography. VLP preparations obtained by the process of the invention are essentially free of endotoxin contaminations.Type: ApplicationFiled: August 22, 2011Publication date: August 23, 2012Applicant: Cytos Biotechnology AGInventors: Susanne Richter, Simon Topell
-
Patent number: 8187607Abstract: The present invention provides compositions comprising a conjugate of a hapten with a carrier in an ordered and repetitive array, and methods of making such compositions. The conjugates and compositions of the invention may comprise a variety of haptens, including hormones, toxins and drugs, especially drugs of addiction such as nicotine. Compositions and conjugates of the invention are useful for inducing immune responses against haptens, which can use useful in a variety of therapeutic, prophylactic and diagnostic regimens. In certain embodiments, immune responses generated using the conjugates, compositions and methods of the present invention are useful to prevent or treat addiction to drugs of abuse and the resultant diseases associated with drug addiction.Type: GrantFiled: October 8, 2008Date of Patent: May 29, 2012Assignee: Cytos Biotechnology AGInventors: Martin F. Bachmann, Patrik Maurer
-
Publication number: 20120114674Abstract: The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen or antigenic determinant array. The invention also provides a process for producing an antigen or antigenic determinant in an ordered and repetitive array. The ordered and repetitive antigen or antigenic determinant is useful in the production of vaccines for the treatment of infectious diseases, the treatment of allergies and as a pharmaccine to prevent or cure cancer and to efficiently induce self-specific immune responses, in particular antibody responses.Type: ApplicationFiled: April 28, 2011Publication date: May 10, 2012Applicants: NOVARTIS PHARMA AG, CYTOS BIOTECHNOLOGY AGInventors: Wolfgang A. Renner, Martin Bachmann, Alain Tissot, Patrick Maurer, Franziska Lechner, Peter Sebbel, Christine Piossek, Rainer Ortmann, Rainer Lüönd, Matthias Staufenbiel, Peter Frey
-
Publication number: 20110305723Abstract: The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen or antigenic determinant array. The invention also provides a process for producing an antigen or antigenic determinant in an ordered and repetitive array. The ordered and repetitive antigen or antigenic determinant is useful in the production of vaccines for the treatment of infectious diseases, the treatment of allergies and as a pharmaccine to prevent or cure cancer and to efficiently induce self-specific immune responses, in particular antibody responses.Type: ApplicationFiled: December 23, 2010Publication date: December 15, 2011Applicant: Cytos Biotechnology AGInventors: Wolfgang A. Renner, Martin Bachmann, Alain Tissot, Patrick Maurer, Franziska Lechner, Peter Sebbel, Christine Piossek
-
Publication number: 20110306113Abstract: The invention provides a process for the purification recombinantly expressed, self-assembled VLP from the homogenate of a bacterial host, wherein the process can be scaled up to a commercial production scale in a cost effective manner. The process comprises a first chromatography using an anion exchange matrix, a second chromatography using hydroxyapatite and, optionally, a size exclusion chromatography. VLP preparations obtained by the process of the invention are essentially free of endotoxin contaminations.Type: ApplicationFiled: December 23, 2010Publication date: December 15, 2011Applicant: Cytos Biotechnology AGInventors: Susanne RICHTER, Simon Topell
-
Publication number: 20110293649Abstract: The invention relates to the finding that stimulation of antigen presenting cell (APC) activation using substances such as anti-CD40 antibodies or DNA oligomers rich in non-methylated C and G (CpGs) can dramatically enhance the specific T cell response obtained after vaccination with recombinant virus like particles (VLPs) coupled, fused or otherwise attached to antigens. While vaccination with recombinant VLPs fused to a cytotoxic T cell (CTL) epitope of lymphocytic choriomeningitis virus induced low levels cytolytic activity only and did not induce efficient anti-viral protection, VLPs injected together with anti-CD40 antibodies or CpGs induced strong CTL activity and full anti-viral protection. Thus, stimulation of APC-activation through antigen presenting cell activators such as anti-CD40 antibodies or CpGs can exhibit a potent adjuvant effect for vaccination with VLPs coupled, fused or attached otherwise to antigens.Type: ApplicationFiled: March 19, 2010Publication date: December 1, 2011Applicant: Cytos Biotechnology AGInventors: Martin F. BACHMANN, Franziska Lechner, Taizo Storni
-
Patent number: 7959924Abstract: The present invention is in the fields of medicine, public health, immunology, molecular biology and virology. The present invention provides, inter alia, a composition comprising a virus-like particle (VLP) and at least one antigen, wherein said antigen is a GIP protein or a GIP fragment linked to the VLP respectively. The invention also provides a method for producing the aforesaid composition. The compositions of this invention are useful in the production of vaccines, in particular, for the prevention and/or treatment of obesity and hereby, in particular, by inducing efficient immune responses, in particular antibody responses. Furthermore, the compositions of the invention are particularly useful to efficiently induce self-specific immune responses within the indicated context. Accordingly, the invention further provides for methods of treating and/or preventing obesity and other conditions.Type: GrantFiled: August 4, 2009Date of Patent: June 14, 2011Assignee: Cytos Biotechnology AGInventors: Martin F. Bachmann, Alma Fulurija, Philippe Saudan
-
Patent number: 7959928Abstract: The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising a virus-like particle (VLP) of an RNA-bacteriophage and at least one antigen, wherein the VLP is recombinantly produced in a host, and wherein the amount of host RNA with secondary structure comprised by the VLP is at most 20% of the amount of host RNA with secondary structure originally comprised by the VLP; and wherein the VLP and the at least one antigen are linked with one another. The invention also provides methods for producing the compositions of the invention. The compositions of the invention are useful in the production of vaccines for the treatment of diseases, disorders and conditions. Furthermore, the compositions of the invention are particularly useful to efficiently induce strong antibody responses against the antigen within the indicated context while lowering or eliminating unwanted T cell responses.Type: GrantFiled: October 5, 2005Date of Patent: June 14, 2011Assignee: Cytos Biotechnology AGInventors: Martin F. Bachmann, Karl G. Proba, Patrik Maurer, Edwin Meijerink, Katrin Schwarz
-
Publication number: 20110097417Abstract: The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a modified virus-like particle (VLP) comprising a VLP which can be loaded with immunostimulatory substances, in particular with DNA oligonucleotides containing non-methylated C and G (CpGs), and particular peptides derived from MelanA linked thereto. Such CpG-VLPs are dramatically more immunogenic than their CpG-free counterparts and induce enhanced B and T cell responses. The immune response against MelanA peptide analogues optionally coupled, fused or attached otherwise to the VLPs is similarly enhanced as the immune response against the VLP itself. In addition, the T cell responses against the MelanA peptide analogues are especially directed to the Th1 type. Antigens attached to CpG-loaded VLPs may therefore be ideal vaccines for prophylactic or therapeutic vaccination against allergies, tumors and other self-molecules and chronic viral diseases.Type: ApplicationFiled: May 11, 2009Publication date: April 28, 2011Applicant: Cytos Biotechnology AGInventors: Martin F. BACHMANN, Vania Manolova, Edwin Meijerink, Karl G. Proba, Katrin Schwarz
-
Publication number: 20110091411Abstract: The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen array, wherein the antigen is an IL-1 mutein. More specifically, the invention provides a composition comprising a virus-like particle, and at least one IL-1 mutein linked thereto. The invention also provides a process for producing the composition. The compositions of the invention are useful in the production of vaccines for the treatment of inflammatory diseases, and chronic autoimmune diseases, genetic diseases and cardiovascular diseases. The composition of the invention efficiently induces immune responses, in particular antibody responses. Furthermore, the compositions of the invention are particularly useful to efficiently induce self-specific immune responses within the indicated context.Type: ApplicationFiled: March 29, 2007Publication date: April 21, 2011Applicant: Cytos Biotechnology AGInventors: Martin F. Bachmann, Gunther Spohn, Alain Tissot
-
Publication number: 20110081642Abstract: The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides methods using a composition comprising an ordered and repetitive antigen or antigenic determinant array for visualization and selection of B cells specific for the antigen. These B cells are useful for the production of monoclonal antibodies used for therapy, diagnostic or research purposes.Type: ApplicationFiled: October 5, 2009Publication date: April 7, 2011Applicant: Cytos Biotechnology AGInventors: Martin F. Bachmann, Dominique Gatto
-
Publication number: 20110081371Abstract: The present invention provides conjugates of peptide derivatives of the mammalian peptide hormones angiotensinogen, angiotensin I and angiotensin II, presented in a repetitive scaffold by coupling the peptide derivatives to a carrier, particularly a virus-like particle (VLP). The invention also provides methods of producing such conjugates, and immunotherapeutic uses of the resulting immunogen conjugates for the therapy and prophylaxis of conditions associated with the renin-activated angiotensin system.Type: ApplicationFiled: December 30, 2009Publication date: April 7, 2011Applicant: Cytos Biotechnology AGInventor: Martin Bachmann
-
Publication number: 20110045013Abstract: The present invention is in the fields of medicine, public health, immunology, molecular biology and virology. The invention provides compositions comprising a virus-like particle (VLP) or a virus particle and at least one antigen, particularly at least one feline antigen, and more particularly at least one feline antigen that is a human allergen. In certain embodiments, the antigen is a Fel d1 antigen or a fragment thereof, covalently linked to the VLP. The invention also provides methods for producing the compositions. The compositions of the invention induce efficient immune responses, in particular antibody responses, in mammals, particularly humans. The compositions and methods of the invention are useful in the production of vaccines, in particular for the treatment and/or prevention of allergies to cat dander and other cat antigens and allergens.Type: ApplicationFiled: May 21, 2010Publication date: February 24, 2011Applicant: Cytos Biotechnology AGInventors: Martin Bachmann, Monika Bauer, Klaus Dietmeier, Nicole Schmitz, Stephan Utzinger
-
Patent number: 7888098Abstract: The invention provides a process for the purification recombinantly expressed, self-assembled VLP from the homogenate of a bacterial host, wherein the process can be scaled up to a commercial production scale in a cost effective manner. The process comprises a first chromatography using an anion exchange matrix, a second chromatography using hydroxyapatite and, optionally, a size exclusion chromatography. VLP preparations obtained by the process of the invention are essentially free of endotoxin contaminations.Type: GrantFiled: June 20, 2006Date of Patent: February 15, 2011Assignee: Cytos Biotechnology AGInventors: Susanne Richter, Simon Topell
-
Publication number: 20110027220Abstract: The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen array, wherein the antigen is an IL-1 protein, an IL-1 mutein or an IL-1 fragment. More specifically, the invention provides a composition comprising a virus-like particle, and at least one IL-1 protein, IL-1 mutein or at least one IL-1 fragment linked thereto. The invention also provides a process for producing the composition. The compositions of the invention are useful in the production of vaccines for the treatment of inflammatory diseases, and chronic autoimmune diseases, genetic diseases and cardiovascular diseases. The composition of the invention efficiently induces immune responses, in particular antibody responses. Furthermore, the compositions of the invention are particularly useful to efficiently induce self-specific immune responses within the indicated context.Type: ApplicationFiled: September 28, 2006Publication date: February 3, 2011Applicant: Cytos Biotechnology AGInventors: Martin Bachmann, Gunther Spohn, Alain Tissot
-
Publication number: 20110008831Abstract: This invention provides a robust fermentation process for the expression of a capsid protein of a bacteriophage which is forming a VLP by self-assembly, wherein the process is scalable to a commercial production scale and wherein the expression rate of the capsid protein is controlled to obtain improved yield of soluble capsid protein. This is achieved by combining the advantages of fed-batch culture and of lactose induced expression systems with specific process parameters providing improved repression of the promoter during the growth phase and high plasmid retention throughout the process.Type: ApplicationFiled: May 24, 2006Publication date: January 13, 2011Applicant: Cytos Biotechnology AGInventors: Marcel Emmerling, Frank Hennecke, Holger Pfründer, Martin Rhiel, Philipp Steiner